Photo via The Globe and Mail

Menopause experts raise concerns after Pfizer discontinues drug in Canada

Read the original at The Globe and Mail ↗
Cite

Kirkup, K., & Hannay, C. (2026, November 19). Menopause experts raise concerns after Pfizer discontinues drug in Canada. The Globe and Mail. https://www.theglobeandmail.com/canada/article-menopause-experts-raise-concerns-after-pfizer-discontinues-premarin/

Dated from the outlet's own feed. Check the original for its byline.

The Globe and Mail · collected 2026-11-19 · by Kristy Kirkup, Chris Hannay

Quick Summary

Menopause specialists are worried about the impact on Canadian patients after Pfizer announced it will stop supplying Premarin vaginal cream and oral estrogen tablets in Canada, despite continuing to offer them in the U.S. Pfizer cited commercial unsustainability due to manufacturing and supply costs, among other factors. The company expects existing inventory to last until next June for the oral tablets and is discontinuing the cream immediately. The decision comes amid rising demand for menopause hormone therapy in Canada, with a 228% increase in hormone-replacement therapy claims among women aged 45 to 54 over five years.
Written by AI on 2026-11-22, from this article's own text only.

AI analysis

Why this leaning score
This article does not take a side on a contested political question, so it has no leaning score. That is an answer rather than a gap: a match report or a rescue can be warmly or critically written without being left or right, and scoring it anyway is how approval of a subject gets recorded as a political position.
No political leaning scored for article 165109 · logged 2026-11-22

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
39
sentences that state something as happening or true
Uncertain
13%
5 of 39 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
51/100
The Globe and Mail's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
unclustered
not grouped into a story yet
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-22 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

The Globe and Mail · 1310 article(s) · 51 correction(s) detected
Running correction rate · 51 correction(s)

Who wrote this

Kristy Kirkup
19 article(s) here · 1 carrying a prediction
Menopause specialists are concerned about how Canadian patients will be affected by Pfizer’s recent decision to stop supplying a vaginal cream and oral estrogen tablets in Canada, while continuing to offer them in the U.S.
Previously, family physicians could apply a consult code for providing menopause care, but many felt the fee was not clearly defined, creating confusion about when it could be used.
“Use them and get going.” Mr. Gibson, 69, knows future research efforts won’t change the fact that ALS, which affects muscles involved in key functions such as breathing, will eventually take his life. But the grandfather, known by his family for his stubborn streak, is determined to push ahead while he can. After being diagnosed with ALS, Mr. Gibson said he had a choice to make: He could either feel bad about his situation or he could do whatever he could with his “last bit of time.” Tammy Moore, chief executive officer of ALS Canada, is urging the government to fund research that could be used to evaluate the demographics of patients across the country and ensure they have access to clinical trials.
Dr. Jerath said a possible explanation for the differences could be that female physicians may engage in more patient-centred communication and that they spend more time with their patients.
So depending on where the attack occurs, you could have a multitude of different symptoms, or you could have no symptoms at all.
By the end of a two-day interjurisdictional meeting, Canada’s provincial and territorial health ministers were able to receive assurances on funding extensions from Ottawa, but will need to convene again before 2027 to confirm the future of expiring transfer programs.
Canada’s provincial and territorial health ministers say Ottawa’s one-year extension of funding for mental health, addiction treatment and home care is not enough, and that federal plans would amount to a spending cut that is “the largest in a generation.”
The model could serve as an example for other centres across the country as Canada experiences rapid growth in its aging population.
An Ontario father of two with Stage 4 melanoma says he is heartbroken that the provincial government’s revised rules for out-of-country medical coverage will continue to bar access to a treatment that could save his and others’ lives.
At the time, a nurse told her any other surgeon would have done a hysterectomy because her situation was “a mess.”
Also by Kristy Kirkup
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 19 articles by Kristy Kirkup →
Chris Hannay
6 article(s) here · 1 carrying a prediction
Menopause specialists are concerned about how Canadian patients will be affected by Pfizer’s recent decision to stop supplying a vaginal cream and oral estrogen tablets in Canada, while continuing to offer them in the U.S.
The charity, which runs the blood system everywhere in Canada but Quebec, would not provide any details about the donor, where the incident happened or precisely when it occurred, preferring to say it happened “earlier in the fall.”
A high-profile defamation trial of several people novelist Steven Galloway says perpetuated false sexual-assault allegations against him is set to begin Monday.
Mr. Gill often went twice a week as one of the ways he gives back to his community, he said – and getting paid up to $70 each time, which he would not be at a Canadian Blood Services centre, was a perk, too.
The company voluntarily stopped collecting plasma in Canada on Aug. 14, saying the pause would be temporary as it worked through improvements to address Health Canada’s concerns. Rodiyat Alabede, a 22-year-old university student, began experiencing cardiac problems during a donation at a Grifols site on Taylor Avenue last October and was pronounced dead at hospital about an hour later. Health Canada told media there was “no linkage” between Ms. Alabede’s death and the donation activity.
Grifols said it would use the temporary closure to retrain staff and work with Health Canada and CBS to improve its operations.
Also by Chris Hannay
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 6 articles by Chris Hannay →

Topics

Canada Canadian Pfizer Premarin U.S.

Subjects

Canada GPE · 6× Pfizer ORG · 6× Canadian NORP · 3× Health Canada ORG · 2× U.S. GPE · 2× Brandon GPE · 1× Man GPE · 1× Manitoba GPE · 1× Saskatchewan GPE · 1× Sophie Morin PERSON · 1×

Narrative

The company “considered a range of factors, including manufacturing and supply costs, the pricing and reimbursement environment, and the ability to maintain sustainable supply over the longer term,” said Sophie Morin, a spokesperson for Pfizer Canada, in an e-mail.
framing: assertive · carried by 1 article(s) · first seen 2026-11-22
Menopause specialists are concerned about how Canadian patients will be affected by Pfizer’s recent decision to stop supplying a vaginal cream and oral estrogen tablets in Canada, while continuing to offer them in the U.S.
2026-11-22 · The Globe and Mail
Menopause experts raise concerns after Pfizer discontinues drug in Canada · assertive framing

Claims (39 extracted, 5 hedged)

Menopause specialists are concerned about how Canadian patients will be affected by Pfizer’s recent decision to stop supplying a vaginal cream and oral estrogen tablets in Canada, while continuing to offer them in the U.S. asserted
patients → concern → U.S.
Physicians say they fear patients will have to contend with the ramifications of Pfizer’s decision, made public last week, to discontinue Premarin cream and tablets in Canada, prescribed to those navigating menopause symptoms. asserted
patients → say → symptoms
Existing inventory is expected to last until next year. asserted
inventory → exist → year
Premarin was first developed and approved in Canada in 1941 and Pfizer manufactures the global supply of the active ingredient in Brandon, Man. asserted
Pfizer → develop → Brandon
It comes from the urine of pregnant mares in Manitoba and Saskatchewan. asserted
It → come → Manitoba
Pfizer first notified Health Canada on Nov. 3 that it would stop supplying Premarin products, according to a federal drug-shortage database. uncertain
it → notify → database
The cream is being discontinued immediately and pills will be available while inventory lasts, potentially until next June, according to notices on the database. uncertain
inventory → discontinue → database
Pfizer said Premarin products were “commercially unsustainable” in Canada. asserted
products → say → Canada
The company “considered a range of factors, including manufacturing and supply costs, the pricing and reimbursement environment, and the ability to maintain sustainable supply over the longer term,” said Sophie Morin, a spokesperson for Pfizer Canada, in an e-mail. asserted
Morin → consider → mail
The federal database shows the Premarin cream has been in shortage four times since the beginning of 2025. asserted
cream → show → 2025
In the U.S., demand has grown for menopause hormone therapy, including after the Food and Drug Administration initiated the removal of long-standing safety warnings on the treatments last November. asserted
Administration → grow → treatments
Health Canada has not removed similar warnings on products here. asserted
Canada → remove → products
In September, a report from Manulife Canada about its group benefits showed a 228-per-cent increase in hormone-replacement therapy claims over five years among women 45 to 54. uncertain
report → show → women
Canadian obstetrician-gynecologist Jen Gunter wrote Wednesday on her blog that Pfizer’s decision should concern all Canadians. asserted
decision → write → Canadians
“This isn’t just about Premarin,” she wrote. asserted
she → write → Premarin
“Every Canadian who cares about access to medications need to be engaged and speak up.” asserted
who → care → medications
In its cream form, Premarin allows for estrogen to be applied directly to vaginal tissue. asserted
estrogen → allow → tissue
It is used to treat atrophic vaginitis, including drying of the vaginal walls, as well as shrinkage of the skin of the vagina and vulva. asserted
It → use → vagina
It can also be used to address dyspareunia, which is pain or discomfort during intercourse. asserted
which → use → intercourse
While there are some alternatives available, Dr. Gunter wrote that Premarin may be better for some patients in terms of side effects and efficacy. uncertain
Premarin → be → effects
Also, physicians say stopping certain treatments can lead to a rebound of symptoms, such as hot flashes and vaginal irritation, and can set back patients in their menopause care. asserted
stopping → say → care
A tube of Premarin cream in Canada typically retails for around $50 because of federal drug rules. asserted
tube → retail → rules
By comparison, it retails for around $400 to $500 in the United States. asserted
it → retail → States
Some patients can access the cream for a lower price if they have insurance coverage. asserted
they → access → coverage
Rithvika Ramesh, a family physician in Toronto, said the discontinuation affects some of her patients. asserted
discontinuation → say → patients
It is the only vaginal estrogen cream covered under the Ontario Drug Benefit program, she said. asserted
she → cover → program
The drug funding plan covers the cost of certain medications for eligible residents. asserted
plan → cover → residents
She said the vaginal cream has long been an important treatment option for patients experiencing genitourinary symptoms of menopause. asserted
cream → say → menopause
Additionally, she said it is used to help prevent recurrent urinary tract infections. asserted
it → say → infections
Dr. Ramesh said for older adults in particular, preventing UTIs can be life-saving, noting that a seemingly uncomplicated infection can progress to kidney infection, hospitalization and, sometimes, sepsis. asserted
infection → say → infection
Sepsis is when the body’s immune system reacts in an extreme way to an infection and it can cause organs to shut down and in some cases, lead to death. asserted
organs → react → death
“Access to effective vaginal estrogen is not simply a matter of quality of life but an important component of preventative health care,” Dr. Ramesh said. asserted
Ramesh → say → care
Lily Barnes, a spokesperson for Ontario Health Minister Sylvia Jones, said vaginal estrogen products identified by the Canadian Menopause Society, including a vaginal ring, tablet and inserts, are still covered on the provincial drug formulary. asserted
products → say → formulary
The Canadian Pharmacists Association has developed a resource for health care providers to manage supply changes, she added. asserted
she → develop → changes
Dr. Ramesh said those who rely on the product may face additional out-of-pocket costs and could have to transition to a product that doesn’t adequately align with their symptoms, preferences and needs. uncertain
that → say → symptoms
Dr. Gunter also voiced concerns about how the discontinuation will affect patients and wants the federal government to get involved in the matter. asserted
government → voice → matter
“The federal government oversees drug approvals and international trade policies,” Dr. Gunter wrote. asserted
Gunter → oversee → approvals
“It is legitimate to ask our elected officials and members of the Senate to find out why this is happening.” asserted
this → ask → Senate
A spokesperson for federal Health Minister Marjorie Michel’s office said that Health Canada is assessing the effects of the discontinuation of Premarin on menopause hormone-therapy supply in Canada, and will act as needed to minimize the impact of shortages. asserted
Canada → say → shortages
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support